Healthcare provider profile · identity verified

Young D Kong, MD

Internal Medicine · OCEAN GROVE, NJ · NPI 1770672412

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	392	48
Amlodipine Besylate	Amlodipine Besylate	343	37
Metformin Hcl	Metformin Hcl	184	21
Pantoprazole Sodium	Pantoprazole Sodium	126	13
Hydrochlorothiazide	Hydrochlorothiazide	116	11
Tamsulosin Hcl	Tamsulosin Hcl	116	14
Simvastatin	Simvastatin	115	11
Lisinopril	Lisinopril	106	12
Losartan Potassium	Losartan Potassium	91	suppressed
Metoprolol Succinate	Metoprolol Succinate	87	suppressed
Famotidine	Famotidine	83	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	81	suppressed
Gabapentin	Gabapentin	79	suppressed
Levothyroxine Sodium	Levothyroxine Sodium	79	11
Omeprazole	Omeprazole	77	suppressed
Folic Acid	Folic Acid	76	suppressed
Furosemide	Furosemide	57	suppressed
Glipizide	Glipizide	57	suppressed
Sertraline Hcl	Sertraline Hcl	56	suppressed
Shingrix	Varicella-Zoster Ge/As01b/Pf	56	45
Rosuvastatin Calcium	Rosuvastatin Calcium	55	suppressed
Clopidogrel	Clopidogrel Bisulfate	54	suppressed
Finasteride	Finasteride	53	suppressed
Januvia	Sitagliptin Phosphate	53	suppressed
Risperidone	Risperidone	52	suppressed
Hydralazine Hcl	Hydralazine Hcl	51	suppressed
Eliquis	Apixaban	49	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	47	suppressed
Benztropine Mesylate	Benztropine Mesylate	42	suppressed
Spironolactone	Spironolactone	42	suppressed
Omega-3 Acid Ethyl Esters	Omega-3 Acid Ethyl Esters	39	suppressed
Aripiprazole	Aripiprazole	38	suppressed
Carvedilol	Carvedilol	38	suppressed
Metformin Hcl Er	Metformin Hcl	35	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	35	suppressed
Propranolol Hcl	Propranolol Hcl	34	suppressed
Vascepa	Icosapent Ethyl	34	suppressed
Olanzapine	Olanzapine	32	suppressed
Mirtazapine	Mirtazapine	29	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	27	suppressed
Midodrine Hcl	Midodrine Hcl	24	suppressed
Trihexyphenidyl Hcl	Trihexyphenidyl Hcl	24	suppressed
Allopurinol	Allopurinol	23	suppressed
Brilinta	Ticagrelor	23	suppressed
Clonidine Hcl	Clonidine Hcl	23	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	23	suppressed
Donepezil Hcl	Donepezil Hcl	22	suppressed
Duloxetine Hcl	Duloxetine Hcl	22	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	22	suppressed
Potassium Chloride	Potassium Chloride	21	suppressed
Montelukast Sodium	Montelukast Sodium	20	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	19	suppressed
Amantadine	Amantadine Hcl	18	suppressed
Myrbetriq	Mirabegron	18	suppressed
Torsemide	Torsemide	18	suppressed
Trazodone Hcl	Trazodone Hcl	17	suppressed
Divalproex Sodium Er	Divalproex Sodium	16	suppressed
Comfort Touch Pen Needle	Pen Needle, Diabetic	15	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	15	suppressed
Levetiracetam	Levetiracetam	15	suppressed
Meloxicam	Meloxicam	15	suppressed
Abrysvo	Rsv Vacc, Pref A And Pref B/Pf	14	14
Fenofibrate	Fenofibrate	14	suppressed
Jardiance	Empagliflozin	13	suppressed
Tradjenta	Linagliptin	13	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	12	suppressed
Enalapril Maleate	Enalapril Maleate	12	suppressed
Entresto	Sacubitril/Valsartan	12	suppressed
Fosinopril Sodium	Fosinopril Sodium	12	suppressed
Hydroxyzine Pamoate	Hydroxyzine Pamoate	12	suppressed
Irbesartan	Irbesartan	12	suppressed
Liothyronine Sodium	Liothyronine Sodium	12	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	12	suppressed
Paroxetine Hcl	Paroxetine Hcl	12	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	12	suppressed
Prazosin Hcl	Prazosin Hcl	12	suppressed
Selegiline Hcl	Selegiline Hcl	12	suppressed
Fenofibrate	Fenofibrate,micronized	11	suppressed
Pravastatin Sodium	Pravastatin Sodium	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error